EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Outcomes Based on Histological Tumor Necrosis and Predictive Clinical and Laboratory Parameters for Necrosis in Children With Osteosarcoma Treated on a Non‐High Dose Methotrexate‐Based Chemotherapy Backbone

Badira Cheriyalinkal Parambil iD, Poonam Khemani, Ajay Puri iD, Ashish Gulia iD, Maya Prasad iD, Venkata Ram Mohan Gollamudi, Mukta Ramadwar, Bharat Rekhi, Poonam Panjwani, Prakash Nayak, Manish Pruthi, Sajid Qureshi iD and 5 more

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31471 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Badira Cheriyalinkal Parambil and 16 co-authors. Institution: Division of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India. Major MEDLINE topics: Osteosarcoma, Methotrexate, Bone Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Cited 1 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Histopathological response to neoadjuvant chemotherapy (NACT) measured as tumor necrosis (TN) has been reported to be prognostic post–high‐dose methotrexate (HDMTX)‐based chemotherapy. We studied this on a non‐HDMTX chemotherapy backbone. Materials and Methods Children ≤15 years, with osteosarcoma treated on OGS‐2012 protocol and surgery post NACT from January 2013 to December 2020 were retrospectively analyzed. TN was expressed as percentage. Outcomes based on different TN cutoffs (used in a dichotomized manner dividing the cohort into two groups of less than/greater than the particular cutoff) and clinical‐laboratory parameters predictive of TN were studied.

Results

Analysis was done in 258 patients. Amputation was performed in 20.1%. Median TN was 94%. At a median follow‐up of 38 months (range: 34–45 months), 3‐year event free survival (EFS) and overall survival (OS) of the whole cohort were 56.1% (SE: 3.3%) and 87.8% (SE: 2.4%). For entire cohort, TN‐70% (29.3% vs. 60.7%), 90% (38.7% vs. 69.0%), 100% (50.8% vs. 84.1%), were prognostic for EFS ( p = 0.0001), while TN‐90% (80.3% vs. 92.9%, p = 0.006) and 100% (85.5% vs. 97.7%, p = 0.023) were prognostic for OS. For localized disease, TN‐70% (35.4% vs. 66.4%), 90% (41.6% vs. 77.0%), 100% (54.8% vs. 96.2%) were prognostic for EFS ( p = 0.0001) and OS ( p = 0.0001). For metastatic disease, TN‐70% was prognostic for EFS (16.6% vs. 50.1%, p = 0.0047). Receiver‐operator curve derived cutoff of 85.5% TN for EFS, 83.5% TN for OS prognosticated whole and localized cohorts the best. For metastatic cohort, 84.5% TN best prognosticated EFS. Among clinical‐laboratory parameters, male gender (OR: 1.9, p = 0.01) and amputation (OR: 2.1, p = 0.014) had a higher risk of less than 90% TN.

Conclusions

Tumor necrosis at 90% cutoff in localized disease is prognostic of survival even on a non‐HDMTX‐based backbone, but exploring other cutoffs for survival predictive and prognostic value could guide future treatment modification strategies and resource allocation in LMICs. Amputation, male gender predicts poor histological necrosis.

Subjects

MeSH terms (MEDLINE)

OsteosarcomaMethotrexateBone NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansChildMaleFemaleRetrospective StudiesNecrosisAdolescentChild, PreschoolPrognosisFollow-Up StudiesSurvival RateNeoadjuvant TherapyInfant

Author keywords

non‐HDMTXosteosarcomaoutcomestumor necrosis

Substances

Methotrexate

Authors and institutions

  • Division of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Nuclear Medicine, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Radiodiagnosis, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Clinical Research Secretariat, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

ORCID profiles: Badira Cheriyalinkal Parambil, Ajay Puri, Ashish Gulia, Maya Prasad, Sajid Qureshi

Cite

APA

Parambil, B. C., Khemani, P., Puri, A., Gulia, A., Prasad, M., Gollamudi, V. R. M., Ramadwar, M., Rekhi, B., Panjwani, P., Nayak, P., Pruthi, M., Qureshi, S., Purandare, N., Janu, A., Pawar, A., Adhav, K., & Chinnaswamy, G. (2025). Outcomes Based on Histological Tumor Necrosis and Predictive Clinical and Laboratory Parameters for Necrosis in Children With Osteosarcoma Treated on a Non‐High Dose Methotrexate‐Based Chemotherapy Backbone. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31471

Vancouver

Parambil BC, Khemani P, Puri A, Gulia A, Prasad M, Gollamudi VRM, et al. Outcomes Based on Histological Tumor Necrosis and Predictive Clinical and Laboratory Parameters for Necrosis in Children With Osteosarcoma Treated on a Non‐High Dose Methotrexate‐Based Chemotherapy Backbone. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31471

BibTeX
@article{Parambil2025,
  author = {Parambil, Badira Cheriyalinkal and Khemani, Poonam and Puri, Ajay and Gulia, Ashish and Prasad, Maya and Gollamudi, Venkata Ram Mohan and Ramadwar, Mukta and Rekhi, Bharat and Panjwani, Poonam and Nayak, Prakash and Pruthi, Manish and Qureshi, Sajid and Purandare, Nilendu and Janu, Amit and Pawar, Akash and Adhav, Komal and Chinnaswamy, Girish},
  title = {Outcomes Based on Histological Tumor Necrosis and Predictive Clinical and Laboratory Parameters for Necrosis in Children With Osteosarcoma Treated on a Non‐High Dose Methotrexate‐Based Chemotherapy Backbone},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31471}
}
Start for free →